Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (131-140 of 218) with videos related to

Pageof 22
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|April 30, 2018
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 studyK B Gordon, A W Armstrong, C Han, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 28, 2014
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective studyK Reich, I Zschocke, H Bachelez, et al.
The British Journal of Dermatology|August 13, 2016
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasisK Reich, A Blauvelt, A Armstrong, et al.
The British Journal of Dermatology|May 19, 2019
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE studyK Reich, L Puig, J C Szepietowski, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
The British Journal of Dermatology|November 16, 2018
Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patientsM Augustin, R Sommer, N Kirsten, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 25, 2023
Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trialsK Reich, M S de Bruin-Weller, M Deleuran, et al.
The American Journal of Pathology|November 7, 2001
Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's diseaseP Middel, P Thelen, S Blaschke, et al.
The British Journal of Dermatology|February 22, 2011
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesK Reich, R G Langley, M Lebwohl, et al.
The British Journal of Dermatology|October 19, 2018
Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis managementM Augustin, A Langenbruch, M Gutknecht, et al.
Pageof 22

Showing results (131-140 of 218) with videos related to

Sort By:
Pageof 22
Journal of the European Academy of Dermatology and Venereology : JEADV|April 30, 2018
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 studyK B Gordon, A W Armstrong, C Han, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 28, 2014
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective studyK Reich, I Zschocke, H Bachelez, et al.
The British Journal of Dermatology|August 13, 2016
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasisK Reich, A Blauvelt, A Armstrong, et al.
The British Journal of Dermatology|May 19, 2019
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE studyK Reich, L Puig, J C Szepietowski, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
The British Journal of Dermatology|November 16, 2018
Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patientsM Augustin, R Sommer, N Kirsten, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 25, 2023
Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trialsK Reich, M S de Bruin-Weller, M Deleuran, et al.
The American Journal of Pathology|November 7, 2001
Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's diseaseP Middel, P Thelen, S Blaschke, et al.
The British Journal of Dermatology|February 22, 2011
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesK Reich, R G Langley, M Lebwohl, et al.
The British Journal of Dermatology|October 19, 2018
Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis managementM Augustin, A Langenbruch, M Gutknecht, et al.
Pageof 22